HLB BioStep Supports IND Approval of Parkinson's Drug with Integrated Non-Clinical Services
HLB BioStep announced that the Parkinson's disease treatment candidate 'YPD-01', for which it provided integrated non-clinical services to facilitate clinical entry, has received approval for a Phase 1 clinical trial investigational new drug (IND) application from the Ministry of Food and Drug Safety.
According to HLB BioStep on July 16, the company, together with its subsidiary HLB BioCode, performed the integrated IND package service for the non-clinical studies of Yebbio's Parkinson's disease treatment candidate 'YPD-01', following the domestic Phase 1 IND approval granted to Yebbio on July 10.
'YPD-01' is the world's first oral disease-modifying therapy (DMT) candidate targeting PARIS (ZNF746), a protein involved in the onset and progression of Parkinson's disease, with the aim of delaying disease progression.
HLB BioStep provided key pharmacokinetic (PK) data necessary for the clinical trial design through PK studies, while HLB BioCode conducted major non-clinical safety evaluation studies required for IND submission, including single and repeated dose toxicity tests, genotoxicity tests, and safety pharmacology studies in compliance with GLP standards.
The company has established an integrated non-clinical service encompassing PK, toxicity, and safety assessment, and recently completed a new drug development platform that supports the entire process from non-clinical to clinical stages in a one-stop manner through collaboration with clinical CROs.
Yebbio, based on the expertise confirmed through this IND approval process with HLB BioStep and HLB BioCode, has also decided to promote additional non-clinical studies needed to enter Phase 2 clinical trials in parallel with Phase 1 trials.
Seongjun Kim, CEO of Yebbio, stated, "Thanks to the systematic support and expertise provided by HLB BioStep and HLB BioCode from non-clinical development to IND submission, we were able to successfully pass the first milestone for clinical entry."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seongjin Baek, CEO of HLB BioStep, said, "The approval of this IND once again proves the competitiveness of the integrated non-clinical service model built by HLB BioStep and HLB BioCode. By further collaborating with clinical CROs, we plan to expand our partnerships with domestic and overseas clients based on our platform that supports the entire drug development lifecycle."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.